Blake Byers has stepped down as a general partner at GV, a corporate venturing arm of US-headquartered internet and technology group Alphabet, to launch what appears to be his own firm, Axios has reported.
Byers has listed Byers Capital in the experience section of his Linkedin profile with the title “Going Solo”.
Byers Capital will invest evenly between technology and biotech companies at series A and B stage, and opportunistically in growth equity deals, according to unnamed sources cited by Axios. GV confirmed that other investors at the firm would take up some of Byers’ board seats at its portfolio companies.
GV hired Byers in 2010 and he mainly invested in life-science and technology developers such as brain chip technology developer Neuralink, drug developer Denali Therapeutics and cancer diagnostics technology producer Grail.
Before joining GV, Byers founded two companies and led research projects on biomedical engineering and stem cell biology at Stanford University.
Photo of Blake Byers courtesy of LinkedIn.